Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$9.86
+1.6%
$11.86
$7.95
▼
$18.48
$1.48B1.834.11 million shs6.60 million shs
Novartis AG stock logo
NVS
Novartis
$160.02
-0.3%
$149.13
$123.24
▼
$170.46
$305.78B0.42.21 million shs1.63 million shs
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$1.63
-5.8%
$2.34
$1.59
▼
$5.48
$105.79M1.21.07 million shs567,068 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
+1.65%-18.58%-13.66%-15.00%+13.33%
Novartis AG stock logo
NVS
Novartis
-0.35%-2.18%+6.24%+3.44%+22.01%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-5.78%-18.09%-14.21%-50.61%-58.52%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$9.86
+1.6%
$11.86
$7.95
▼
$18.48
$1.48B1.834.11 million shs6.60 million shs
Novartis AG stock logo
NVS
Novartis
$160.02
-0.3%
$149.13
$123.24
▼
$170.46
$305.78B0.42.21 million shs1.63 million shs
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$1.63
-5.8%
$2.34
$1.59
▼
$5.48
$105.79M1.21.07 million shs567,068 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
+1.65%-18.58%-13.66%-15.00%+13.33%
Novartis AG stock logo
NVS
Novartis
-0.35%-2.18%+6.24%+3.44%+22.01%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-5.78%-18.09%-14.21%-50.61%-58.52%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2.33
Hold$21.44117.49% Upside
Novartis AG stock logo
NVS
Novartis
2.17
Hold$152.25-4.86% Downside
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
2.67
Moderate Buy$25.001,433.74% Upside

Current Analyst Ratings Breakdown

Latest VYGR, NVS, and NTLA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
11/13/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Set Price Target$30.00
11/13/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Reiterated RatingMarket Outperform
11/4/2026
Novartis AG stock logo
NVS
Novartis
DowngradeBuy (B) ➝ Buy (B-)
10/30/2026
Novartis AG stock logo
NVS
Novartis
DowngradeHold ➝ Sell
10/28/2026
Novartis AG stock logo
NVS
Novartis
Reiterated RatingSector Perform
10/28/2026
Novartis AG stock logo
NVS
Novartis
Reiterated RatingNeutral
10/28/2026
Novartis AG stock logo
NVS
Novartis
Reiterated RatingOverweight$163.00
10/28/2026
Novartis AG stock logo
NVS
Novartis
Initiated CoverageHold
10/22/2026
Novartis AG stock logo
NVS
Novartis
Reiterated RatingBuy (B)
10/15/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Reiterated RatingSell (D-)
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$67.67M20.45N/AN/A$4.37 per share2.26
Novartis AG stock logo
NVS
Novartis
$54.53B5.60$10.73 per share14.92$19.69 per share8.13
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$40.37M2.51N/AN/A$2.17 per share0.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$412.69M-$3.35N/AN/AN/A-805.75%-64.74%-50.72%N/A
Novartis AG stock logo
NVS
Novartis
$13.98B$5.2430.5416.022.9318.11%41.04%14.45%2/3/2027 (Estimated)
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$119.72M-$1.73N/AN/AN/A-416.32%-63.42%-49.40%N/A

Latest VYGR, NVS, and NTLA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$0.7970-$0.91-$0.1130-$0.91$9.74 million$7.16 million
11/5/2026Q3 2026
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.4188-$0.40+$0.0188-$0.40$6.35 million$0.61 million
10/27/2026Q3 2026
Novartis AG stock logo
NVS
Novartis
$2.25$2.46+$0.21$0.63$14.53 billion$15.03 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/AN/AN/AN/AN/A
Novartis AG stock logo
NVS
Novartis
$3.081.92%+5.28%58.78%N/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/A
6.31
6.65
Novartis AG stock logo
NVS
Novartis
0.98
0.88
0.70
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/A
6.81
7.51

Institutional Ownership

CompanyInstitutional Ownership
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
88.77%
Novartis AG stock logo
NVS
Novartis
13.12%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
48.03%

Insider Ownership

CompanyInsider Ownership
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
3.50%
Novartis AG stock logo
NVS
Novartis
0.01%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
12.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
377140.36 million135.45 millionOptionable
Novartis AG stock logo
NVS
Novartis
75,2671.91 billion1.91 billionOptionable
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
14162.23 million54.33 millionOptionable

Recent News About These Companies

Voyager Therapeutics stock trades at 1.76 euros Tuesday
Voyager Reports Third Quarter 2026 Financial and Operating Results
Voyager Therapeutics stock trades at EUR 1.71 on Thursday
Voyager Therapeutics (VYGR) Gets a Buy from Wells Fargo

New MarketBeat Followers Over Time

Media Sentiment Over Time

Intellia Therapeutics stock logo

Intellia Therapeutics NASDAQ:NTLA

$9.86 +0.16 (+1.65%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$9.86 0.00 (-0.05%)
As of 08:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Novartis stock logo

Novartis NYSE:NVS

$160.02 -0.48 (-0.30%)
Closing price 11/16/2026 03:59 PM Eastern
Extended Trading
$158.77 -1.25 (-0.78%)
As of 08:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Voyager Therapeutics stock logo

Voyager Therapeutics NASDAQ:VYGR

$1.63 -0.10 (-5.78%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.64 +0.01 (+0.55%)
As of 07:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.